Key result
Early-pregnancy PFOA linked to lower postpartum levels of key cardiovascular proteins including VEGFD.
Why the study?
Are higher PFAS levels during early pregnancy associated with altered circulating cardiovascular proteins at 3 years postpartum in women?
Cohort (n=173)
Are higher PFAS levels during early pregnancy associated with altered circulating cardiovascular proteins at 3 years postpartum in women?
p-value: p=<0.10
PFAS exposure during early pregnancy is associated with long-term alterations in cardiovascular proteins related to inflammation and vascular remodeling, highlighting potential mechanisms for cardiovascular risk.
Introduction: PFAS are synthetic chemicals that persist in the environment and accumulate in humans. Higher PFAS exposure during pregnancy has been associated with poorer long-term cardiovascular health in women, but the biological pathways are unclear. Circulating cardiovascular proteins may help elucidate these mechanisms. Methods: We studied 173 women from Project Viva, a prospective cohort enrolled between 1999 and 2002 in Eastern MA. We measured plasma concentrations of 6 PFAS (PFOA, PFOS, PFHxS, PFNA, EtFOSAA, MeFOSAA) during early pregnancy. In plasma collected at 3 years postpartum, we quantified 92 proteins using the Olink Target 92 Cardiovascular II panel. We used linear regression models to examine associations of each log 2 -transformed PFAS with Normalized Protein eXpression (NPX) levels, adjusting for age at enrollment, education, marital status, pre-pregnancy BMI, parity, smoking status, and first-trimester DASH diet score. We report associations with nominal P <0.05 and used the False Discovery Rate (FDR) approach to account for multiple testing, considering FDR<0.10 as statistically significant. Results: The mean (SD) age at enrollment was 33.0 (4.8) years; 80% were college graduates, and 50% were nulliparous. In adjusted models, PFOA, PFOS, PFHxS, PFNA, EtFOSAA, and MeFOSAA were associated with 6, 7, 9, 4, 8, and 3 proteins, respectively, at nominal P <0.05 ( Figure ). Nine proteins, including vascular endothelial growth factor D (VEGFD), tumor necrosis factor receptor superfamily member 13B (TNFRSF13B), SLAM family member 7 (SLAMF7), interleukin-1 receptor-like 2 (IL1RL2), kit ligand (SCF), galectin-9 (Gal-9), C-C motif chemokine 3 (CCL3), pro-adrenomedullin (ADM), and macrophage receptor MARCO, were each associated with ≥ 2 PFAS at nominal P <0.05; Table summarizes the cardiovascular relevance of these proteins. After FDR correction, PFOA remained associated with lower levels of VEGFD (implicated in endothelial dysfunction and vascular remodeling), TNFRSF13B (implicated in adaptive immunity and chronic inflammation), and SLAMF7 (implicated in macrophage inflammation and foam cell formation) ( Figure ). No other PFAS-protein associations reached FDR<0.10. Conclusion: PFAS levels during pregnancy were associated with alterations in multiple cardiovascular proteins involved in inflammation, vascular remodeling, and atherosclerosis at 3 years postpartum. These results suggest potential pathways linking PFAS to women’s long-term cardiovascular health.
No takes yet. Share an insight, caveat, or question.
Grobman et al. (2026) conducted a cohort in Postpartum cardiovascular health (n=173). Per- and polyfluoroalkyl substance (PFAS) levels during early pregnancy was evaluated on Circulating cardiovascular protein levels (Normalized Protein eXpression) at 3 years postpartum (p=<0.10). Higher PFOA levels during early pregnancy were significantly associated with lower levels of cardiovascular proteins VEGFD, TNFRSF13B, and SLAMF7 at 3 years postpartum (FDR<0.10).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: